University of Hertfordshire

From the same journal

From the same journal

By the same authors

Documents

  • Pan Li
  • Catpagavalli Asokanathanb
  • Fang Liu
  • Kyi Kyi Khaing
  • Dorota Kmiec
  • Xiaoqing Wei
  • Bin Song
  • Dorothy Xing
  • Deling Kong
View graph of relations
Original languageEnglish
Pages (from-to)183-190
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume513
Issue1-2
Early online date29 Aug 2016
DOIs
Publication statusPublished - 20 Nov 2016

Abstract

Poly(lactic-co-glycolic acid) (PLGA) based nano/micro particles were investigated as a potential vaccine platform for pertussis antigen. Presentation of pertussis toxoid as nano/micro particles (NP/MP) gave similar antigen-specific IgG responses in mice compared to soluble antigen. Notably, in cell line based assays, it was found that PLGA based nano/micro particles enhanced the phagocytosis of fluorescent antigen-nano/micro particles by J774.2 murine monocyte/macrophage cells compared to soluble antigen. More importantly, when mice were immunised with the antigen-nano/micro particles they significantly increased antigen-specific Th1 cytokines INF-γ and IL-17 secretion in splenocytes after in vitro re-stimulation with heat killed Bordetalla pertussis, indicating the induction of a Th1/Th17 response. Also, presentation of pertussis antigen in a NP/MP formulation is able to provide protection against respiratory infection in a murine model. Thus, the NP/MP formulation may provide an alternative to conventional acellular vaccines to achieve a more balanced Th1/Th2 immune response.

Notes

This document is the Accepted Manuscript version of the following article: Pan Li, Catpagavalli Asokanathan, Fang Liu, Kyi Kyi Khaing, Dorota Kmiec, Xiaoqing Wei, Sing Song, Dorothy Xing, and Deling Kong, ‘PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model’, International Journal of Pharmaceutics, Vol. 513 (1-2): 183-190, November 2016, available online at: https://doi.org/10.1016/j.ijpharm.2016.08.059. This manuscript version is made available under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives LicenseCC BY NC-ND 4.0 ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

ID: 11091922